English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: Hepatitis C virus (HCV) infection is a leading cause of Chronic Liver Disease (CLD) and liver transplantation globally. Currently, oral combinations of Direct Acting Antiviral agents (DAAs) are the standard of care for treating chronic HCV infection. Aim of Study: To assess the efficacy & safety of combination of Daclatasvir and Sofosbuvir in Egyptian patients with chronic hepatitis C Genotype 4 and Cirrhosis. Patients and Methods: 50 Egyptian, cirrhotic patients with HCV genotype 4 infection were treated with a generic form of sofosbuvir (SOF) 400mg, daclatasvir (DCV) 60mg with or without weight-based ribavirin (RBV) for only 12 weeks. 40 out of the 50 patients enrolled in the study, completed treatment, while the remaining 10 patients were lost for follow-up. Results: The 12 weeks combination of SOF plus DCV achieved SVR in all treated patients (100%) whether treatmentnaïve or experienced, with or without ribavirin. A significant improvement was observed in transaminases, while a nonsignificant improvement was observed in serum albumin, bilirubin, INR and the mean CTP score indicating improvement in liver functions. Regarding safety outcomes, all treatmentrelated AEs were only minor AEs with no major AEs. Conclusion: The combination of SOF plus DCV with or without RBV for only 12 weeks is highly effective in treating HCV GT4 cirrhotic patients with SVR12 rate of 100%, safe and well tolerated by these cirrhotic patients. Moreover, there was a marginal improvement in liver functions observed 12 weeks after treatment.

Efficacy and Safety of Daclatasvir and Sofosbuvir in Egyptian Patients with Chronic Hepatitis C Genotype 4 and Cirrhosis